AIM ImmunoTech Inc. (AIM)
NYSE
Closed
Oct 9, 2026
Day's Range
0.177052 wk Range
0.1700Profile - AIM - AIM ImmunoTech Inc.
Profile
Mic Code
XASE
Sector
Healthcare
Industry
Biotechnology
Employees
19
AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.
Profile Details
Type
Common Stock
Address
2117 SW Highway 484
City
Ocala
State
FL
Zip
34473
Country
United States
Phone
352 448 7797
Key Executives - AIM - AIM ImmunoTech Inc.
Key executives
Cross Listings - AIM - AIM ImmunoTech Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
